UBS made no change to the firm’s Buy rating or $16 price target on shares of Teva. Following meetings with the company’s management, UBS has increased confidence in its fiscal 2024 estimates and continued growth trajectory, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on TEVA: